May 14, 2008 — The blocking of epidermal growth-factor receptors (EGFR) to treat non-small-cell lung cancer is becoming increasingly common, but there is considerable debate about when to initiate ...

Biocartis’ Idylla EGFR Mutation Test has secured the EU Technical Documentation Assessment and Quality Management System certificate, making it the first Idylla Test to achieve Class C companion ...

DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial.

Diabetes and kidney disease are major risk factors for heart disease, yet many cases are undiagnosed. In addition, a consumer survey done last fall suggests that most people don't realize that their ...